Impact of Frontline Systemic Treatment Choice on Clinical Outcome in Advanced Leiomyosarcoma: A CanSaRCC Study
Cancer Medicine · 2026-07 · 15 (7)
DOI: 10.1002/cam4.72080 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 14.07.2026. Verfasst von Erica C Koch Hein und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Princess Margaret Cancer Centre and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leiomyosarcoma, Uterine Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Frontline systemic treatment selection for advanced leiomyosarcoma (LMS) remains variable in routine practice. Gemcitabine‐based regimens are frequently used despite randomized evidence of non‐superiority compared with doxorubicin‐based regimens and greater complexity in treatment delivery.
Methods
This multi‐centre retrospective cohort study included advanced/metastatic LMS patients treated with frontline doxorubicin‐ or gemcitabine‐based chemotherapy at four Canadian sarcoma centres (2010–2022). The primary endpoint was overall survival (OS). Secondary endpoints were time to second‐line treatment (T2T) and number of subsequent systemic treatment lines. Subgroup analyses were conducted by primary tumor site (uterine vs. non‐uterine LMS).
Results
Among 217 patients, median OS was 17.1 months (95% CI 14.8–21.1). OS did not differ between frontline doxorubicin‐ and gemcitabine‐based regimens (17.8 vs. 16.1 months; p = 0.16), nor did T2T (5.8 vs. 6.3 months; p = 0.77). Non‐uterine primary site and surgery following frontline systemic treatment were independently associated with improved OS. Median OS was longer for non‐uterine versus uterine LMS (23 vs. 12.8 months; p < 0.001).
Conclusions
In this large real‐world LMS cohort, outcomes were not influenced by frontline chemotherapy choice. These findings support prioritizing toxicity, quality of life, cost, and treatment delivery burden when selecting frontline therapy, particularly where doxorubicin/trabectedin use is limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Princess Margaret Cancer Centre and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
- Pontificia Universidad Católica de Chile, Santiago, Chile.
- Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada.
- Division of Radiation Oncology, BC Cancer, University of British Columbia, Victoria, British Columbia, Canada.
- Department of Surgery, The Ottawa Hospital and Research Institute, University of Ottawa, Ottawa, Canada.
- Department of Biostatistics, University Health Network, Toronto, Canada.
ORCID-Profile: Caroline Holloway, Abdulazeez Salawu
Zitieren
APA
Hein, E. C. K., Gupta, A., Soroka, H. P., Holloway, C., Biffart, B., Nessim, C., Wild, T., Lajkosz, K., Watson, G. A., Razak, A. A., & Salawu, A. (2026). Impact of Frontline Systemic Treatment Choice on Clinical Outcome in Advanced Leiomyosarcoma: A CanSaRCC Study. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72080
Vancouver
Hein ECK, Gupta A, Soroka HP, Holloway C, Biffart B, Nessim C, et al. Impact of Frontline Systemic Treatment Choice on Clinical Outcome in Advanced Leiomyosarcoma: A CanSaRCC Study. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72080
BibTeX
@article{Hein2026,
author = {Hein, Erica C Koch and Gupta, Abha and Soroka, Hagit Peretz and Holloway, Caroline and Biffart, Brookelyn and Nessim, Carolyn and Wild, Tristan and Lajkosz, Katherine and Watson, Geoffrey A and Razak, Albiruni Abdul and Salawu, Abdulazeez},
title = {Impact of Frontline Systemic Treatment Choice on Clinical Outcome in Advanced Leiomyosarcoma: A CanSaRCC Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/cam4.72080}
}
EUVIMED